Sign in
CompletedNo phase

Mechanisms of Palmitoylethanolamide (PEA) to Alter Pain Sensitivity in Knee Osteoarthritis

Key facts

Who runs it
University of Maryland, Baltimore
Where
Baltimore, United StatesSee the site
Trial code
Status
Completed
People taking part
13 people enrolled
Started
22 Mar 2023
Ended
2 Jan 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • palmitoylethanolamide
  • Placebo
Record updated
5 November 2024

Who can take part

Age
40 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Adults aged 40 to 80
  • English speaking
  • Self reported diagnosis of osteoarthritis in one or both knees
  • Self-reported average knee pain over the past month at least 4 out of 10 on a 0-10 numeric rating scale
  • Agreement to abstain from all osteoarthritis pain medication (such as non-steroidal anti-inflammatory drugs or narcotics) and use only acetaminophen as a rescue medication when needed
  • Can pass an evaluation to sign consent

Who cannot take part

  • Knee surgery in past 12 months or total knee replacement
  • Oral or intra-articular glucocorticoid use in the prior 3 months; intra-articular hyaluronate use in the prior 6 months
  • Any of the following conditions: chronic kidney disease stage 3-5, unstable angina, congestive heart failure, cancer or cancer treatment (except skin)
  • Allergy to oat, coconut, citrus, olive, or sunflower oils, or maltodextrin
  • Inflammatory arthritis (eg. Rheumatoid arthritis)
  • Knee injury in past 6 months
  • Pregnant or breastfeeding
  • enrolled in other knee OA rehabilitation programs or clinical trials
  • Opioid use in the past month

Where in United States

  • University of Maryland, BaltimoreBaltimore, United States

About the trial

What the trial wants to find out

The purposes of this 1-year proof of feasibility and acceptability pilot study are twofold. First to determine if participants with knee osteoarthritis (KOA) will comply with taking palmitoylethanolamide (PEA) dietary supplement for 6 weeks and adhere to taking it as directed. Second is to gain preliminary data to elucidate mechanisms (protein signatures, inflammatory markers and neurobiological signaling pathways) by which PEA, a lipid-based endocannabinoid, works to alter pain sensitivity in adults with KOA. In the simplest terms possible, we need to provide evidence that PEA changes the protein signature in order to provide evidence to establish mechanism.

The 2 groups in the trial

  • palmitoylethanolamide (PEA)Treatment being tested

    Palmitoylethanolamide (PEA) is a lipid based endocannabinoid dietary supplement currently marketed.

    Treatment: palmitoylethanolamide

  • PlaceboPlacebo, for comparison

    A similar size and shaped capsule containing maltodextrin will be used as a placebo comparator.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
5 November 2024